Virucidal efficacy of guanidine-free inactivants and rapid test buffers against SARS-CoV-2

Katherine Davies; Ulrike Arnold; Hubert Buczkowski; Christopher Burton; Stephen R. Welch; Nicole Green; Rhea Strachan; Tracy Beetar-King; Peter Spencer; Nipunadi Hettiarachchi; Matthew J. Hannah; Matthew Jones; Patricia A. Cane; Christine B. Bruce; Neil Woodford; Allen D.G. Roberts; Marian J. Killip

doi:10.1038/s41598-021-02942-4

Virucidal efficacy of guanidine-free inactivants and rapid test buffers against SARS-CoV-2

Katherine Davies, Ulrike Arnold, Hubert Buczkowski, Christopher Burton, Stephen R. Welch, Nicole Green, Rhea Strachan, Tracy Beetar-King, Peter Spencer, Nipunadi Hettiarachchi, Matthew J. Hannah, Matthew Jones, Patricia A. Cane, Christine B. Bruce, Neil Woodford, Allen D.G. Roberts, Marian J. Killip^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

128 Downloads (Pure)

Abstract

A pathogen inactivation step during collection or processing of clinical samples has the potential to reduce infectious risks associated with diagnostic procedures. It is essential that these inactivation methods are demonstrated to be effective, particularly for non-traditional inactivation reagents or for commercial products where the chemical composition is undisclosed. This study assessed inactivation effectiveness of twenty-four next-generation (guanidine-free) nucleic acid extraction lysis buffers and twelve rapid antigen test buffers against SARS-CoV-2, the causative agent of COVID-19. These data have significant safety implications for SARS-CoV-2 diagnostic testing and support the design and evidence-based risk assessment of these procedures.

Original language	English
Article number	23379
Number of pages	7
Journal	Scientific Reports
Volume	11
Issue number	1
DOIs	https://doi.org/10.1038/s41598-021-02942-4
Publication status	Published - 3 Dec 2021

Bibliographical note

Funding Information: This work was supported by Public Health England. The views expressed are those of the authors and not necessarily those of Public Health England or the Department of Health.

Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Publisher Copyright: © 2021, The Author(s).

Citation: Davies, K., Arnold, U., Buczkowski, H. et al. Virucidal efficacy of guanidine-free inactivants and rapid test buffers against SARS-CoV-2. Sci Rep 11, 23379 (2021).

DOI: https://doi.org/10.1038/s41598-021-02942-4

Access to Document

10.1038/s41598-021-02942-4Licence: CC BY

Davies2021VirucidalEfficacyOfGuanidine-FreeInactivantsSciRepFinal published version, 1.08 MBLicence: CC BY

Cite this

Davies, K., Arnold, U., Buczkowski, H., Burton, C., Welch, S. R., Green, N., Strachan, R., Beetar-King, T., Spencer, P., Hettiarachchi, N., Hannah, M. J., Jones, M., Cane, P. A., Bruce, C. B., Woodford, N., Roberts, A. D. G., & Killip, M. J. (2021). Virucidal efficacy of guanidine-free inactivants and rapid test buffers against SARS-CoV-2. Scientific Reports, 11(1), Article 23379. https://doi.org/10.1038/s41598-021-02942-4

@article{3c92c4b314a14df7bf01b1938e02c119,

title = "Virucidal efficacy of guanidine-free inactivants and rapid test buffers against SARS-CoV-2",

abstract = "A pathogen inactivation step during collection or processing of clinical samples has the potential to reduce infectious risks associated with diagnostic procedures. It is essential that these inactivation methods are demonstrated to be effective, particularly for non-traditional inactivation reagents or for commercial products where the chemical composition is undisclosed. This study assessed inactivation effectiveness of twenty-four next-generation (guanidine-free) nucleic acid extraction lysis buffers and twelve rapid antigen test buffers against SARS-CoV-2, the causative agent of COVID-19. These data have significant safety implications for SARS-CoV-2 diagnostic testing and support the design and evidence-based risk assessment of these procedures.",

author = "Katherine Davies and Ulrike Arnold and Hubert Buczkowski and Christopher Burton and Welch, {Stephen R.} and Nicole Green and Rhea Strachan and Tracy Beetar-King and Peter Spencer and Nipunadi Hettiarachchi and Hannah, {Matthew J.} and Matthew Jones and Cane, {Patricia A.} and Bruce, {Christine B.} and Neil Woodford and Roberts, {Allen D.G.} and Killip, {Marian J.}",

note = "Funding Information: This work was supported by Public Health England. The views expressed are those of the authors and not necessarily those of Public Health England or the Department of Health. Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article{\textquoteright}s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article{\textquoteright}s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Publisher Copyright: {\textcopyright} 2021, The Author(s). Citation: Davies, K., Arnold, U., Buczkowski, H. et al. Virucidal efficacy of guanidine-free inactivants and rapid test buffers against SARS-CoV-2. Sci Rep 11, 23379 (2021). DOI: https://doi.org/10.1038/s41598-021-02942-4",

year = "2021",

month = dec,

day = "3",

doi = "10.1038/s41598-021-02942-4",

language = "English",

volume = "11",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Research",

number = "1",

}

Davies, K, Arnold, U, Buczkowski, H, Burton, C, Welch, SR, Green, N, Strachan, R, Beetar-King, T, Spencer, P, Hettiarachchi, N, Hannah, MJ, Jones, M, Cane, PA, Bruce, CB, Woodford, N, Roberts, ADG & Killip, MJ 2021, 'Virucidal efficacy of guanidine-free inactivants and rapid test buffers against SARS-CoV-2', Scientific Reports, vol. 11, no. 1, 23379. https://doi.org/10.1038/s41598-021-02942-4

TY - JOUR

T1 - Virucidal efficacy of guanidine-free inactivants and rapid test buffers against SARS-CoV-2

AU - Davies, Katherine

AU - Arnold, Ulrike

AU - Buczkowski, Hubert

AU - Burton, Christopher

AU - Welch, Stephen R.

AU - Green, Nicole

AU - Strachan, Rhea

AU - Beetar-King, Tracy

AU - Spencer, Peter

AU - Hettiarachchi, Nipunadi

AU - Hannah, Matthew J.

AU - Jones, Matthew

AU - Cane, Patricia A.

AU - Bruce, Christine B.

AU - Woodford, Neil

AU - Roberts, Allen D.G.

AU - Killip, Marian J.

N1 - Funding Information: This work was supported by Public Health England. The views expressed are those of the authors and not necessarily those of Public Health England or the Department of Health. Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. Publisher Copyright: © 2021, The Author(s). Citation: Davies, K., Arnold, U., Buczkowski, H. et al. Virucidal efficacy of guanidine-free inactivants and rapid test buffers against SARS-CoV-2. Sci Rep 11, 23379 (2021). DOI: https://doi.org/10.1038/s41598-021-02942-4

PY - 2021/12/3

Y1 - 2021/12/3

N2 - A pathogen inactivation step during collection or processing of clinical samples has the potential to reduce infectious risks associated with diagnostic procedures. It is essential that these inactivation methods are demonstrated to be effective, particularly for non-traditional inactivation reagents or for commercial products where the chemical composition is undisclosed. This study assessed inactivation effectiveness of twenty-four next-generation (guanidine-free) nucleic acid extraction lysis buffers and twelve rapid antigen test buffers against SARS-CoV-2, the causative agent of COVID-19. These data have significant safety implications for SARS-CoV-2 diagnostic testing and support the design and evidence-based risk assessment of these procedures.

AB - A pathogen inactivation step during collection or processing of clinical samples has the potential to reduce infectious risks associated with diagnostic procedures. It is essential that these inactivation methods are demonstrated to be effective, particularly for non-traditional inactivation reagents or for commercial products where the chemical composition is undisclosed. This study assessed inactivation effectiveness of twenty-four next-generation (guanidine-free) nucleic acid extraction lysis buffers and twelve rapid antigen test buffers against SARS-CoV-2, the causative agent of COVID-19. These data have significant safety implications for SARS-CoV-2 diagnostic testing and support the design and evidence-based risk assessment of these procedures.

UR - http://www.scopus.com/inward/record.url?scp=85120910054&partnerID=8YFLogxK

U2 - 10.1038/s41598-021-02942-4

DO - 10.1038/s41598-021-02942-4

M3 - Article

AN - SCOPUS:85120910054

SN - 2045-2322

VL - 11

JO - Scientific Reports

JF - Scientific Reports

IS - 1

M1 - 23379

ER -

Virucidal efficacy of guanidine-free inactivants and rapid test buffers against SARS-CoV-2

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this